WS
CDTX

Wedbush Securities’s Cidara Therapeutics CDTX Stock Holding History

Wedbush Securities’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-803
Closed -$43K – 995
2019
Q1 		$43K Sell
803
-100
-11% -$5.48K ﹤0.01% 900
2018
Q4 		$42K Hold
903
– – 0.01% 801
2018
Q3 		$79K Hold
903
– – 0.01% 851
2018
Q2 		$94K Sell
903
-185
-17% -$17.5K 0.01% 814
2018
Q1 		$87K Buy
+1,088
New +$149K 0.01% 764

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Wedbush Securities's CDTX Position: Q2 2019 in Review

Wedbush Securities sold out of Cidara Therapeutics (CDTX) in Q2 2019, closing a stake of 803 shares — an estimated $43K sold.

Wedbush Securities first reported a position in CDTX in Q1 2018 and held it in 5 quarters. The position peaked at $94K in Q2 2018. 45 funds tracked by Wall St. Rank hold CDTX as of Q2 2019.

  • Wedbush Securities reported no remaining Cidara Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Wedbush Securities sold 803 Cidara Therapeutics shares in Q2 2019, an estimated $43K.
  • Wedbush Securities first reported a position in Cidara Therapeutics in Q1 2018 and held it in 5 quarters.
  • Wedbush Securities's Cidara Therapeutics position peaked at $94K in Q2 2018.
  • 45 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2019.

Based on Wedbush Securities's 13F filing for Q2 2019, filed 1 Aug 2019.